Kalaris Therapeutics Inc
KLRSHealthcare|Biotechnology|US
$2.42
+0.06 (+2.54%)
DCF Value
$6.25
Tangible Book / Share
$2.42
Cash / Share
$3.93
About
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.
Stock Price
-48.8%(1Y)
1M
-3.2%
3M
-40.5%
6M
-52.4%
YTD
-71.3%
1Y
-49.6%
3Y
-99.7%
5Y
-100.0%
Pipeline Summary
0 total trials0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Key Facts
Market Cap$57.6M
Employees20
CEOAndrew Oxtoby
IPO DateJul 30, 2020
Beta0.21
52-Week Range$1.78 – $11.88
Avg Volume201,180
ExchangeNASDAQ
Websitekalaristx.com
Ownership
Float36.3%
Shares Outstanding23.8M
Recent Insider Trades
Vandekop Amy O'LearyAWARD
Aug 27, 202610,000 shares @ $4.10
KEATING LAURIEAWARD
Aug 1, 202618,000 shares @ $3.51
KEATING LAURIEOTHER
Aug 1, 20260 shares
Vandekop Amy O'LearyOTHER
Jul 27, 20260 shares
Vandekop Amy O'LearyOTHER
Jul 27, 202627,415 shares @ $7.31
Peers
Recent News
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Stock Has Average Price Target of $18.75
Sep 28, 2026 · defenseworld.net
Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference
Aug 31, 2026 · globenewswire.com
Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates
Aug 11, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:18 AM